Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
Mayo Clinic
Hoffmann-La Roche
Fluidx Medical Technology, Inc.
ViroMissile, Inc.
AstraZeneca
National Institutes of Health Clinical Center (CC)
Canadian Cancer Trials Group
St. Jude Children's Research Hospital
MacroGenics
Alliance for Clinical Trials in Oncology
City of Hope Medical Center
Ocellaris Pharma, Inc.
iOmx Therapeutics AG
Memorial Sloan Kettering Cancer Center
HiFiBiO Therapeutics
St. Jude Children's Research Hospital
Milton S. Hershey Medical Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
HiFiBiO Therapeutics
Actym Therapeutics, Inc.
Novelty Nobility, Inc.
Travera Inc
Kazia Therapeutics Limited
NextPoint Therapeutics, Inc.
Stanford University
Stanford University
University Hospital, Antwerp
GI Innovation, Inc.
Xencor, Inc.
Gustave Roussy, Cancer Campus, Grand Paris
Pfizer
DNAtrix, Inc.
Ipsen
Albert Einstein College of Medicine
National Cancer Institute (NCI)
Masonic Cancer Center, University of Minnesota
Corvus Pharmaceuticals, Inc.
M.D. Anderson Cancer Center
Sumitomo Pharma America, Inc.
SCRI Development Innovations, LLC
Tempest Therapeutics
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Nektar Therapeutics